Trulieve Q2 2026: Tax Relief Masks the Revenue Problem

Trulieve reported Q2 2026 results today with a headline that would make a GAAP reader nervous and an adjusted-metrics reader relieved. The GAAP net loss was $406 million. Adjusted net income was $20.4 million, a turn from a $7.7 million loss in Q2 2025. Both numbers are right, and they're telling different stories about the same quarter.

The $406 million GAAP hole is dominated by a $403.3 million non-cash charge from the June 3 deconsolidation of Harvest Time Holdings — the mixed-use cannabis unit Trulieve separated from its medical business to meet NYSE listing standards. You can subtract that charge without losing sleep. The adjusted view is the one that carries weight.

But even the adjusted view has something that doesn't add up. Revenue fell 10% year-over-year to $271 million, and the company turned a profit. That's not operating leverage — that's tax relief, and it's the single most important thing to understand about this quarter.

The Schedule III effect

In April 2026, the federal government rescheduled medical marijuana from Schedule I to Schedule III, with retroactive effect to January 1, 2026. For a company like Trulieve, whose medical cannabis revenue makes up roughly 75% of sales, this removed the IRS Code 280E restriction that had prevented cannabis operators from deducting ordinary business expenses. The tax burden that used to devour 70% or more of pre-tax income has been dramatically reduced.

That's why adjusted net income flipped positive while revenue declined. It's why Q1 2026 showed $2 million of net income as well. The tax environment is no longer a profit-destroying anomaly. It's the structural change that made profitability possible in the first place.

What the operating metrics say

Revenue of $271 million was down from $302 million in Q2 2025. Gross margin held at 60%, one point below the prior year. On the surface, 60% is still a durable number for a multi-state operator — but it's not improving, and it was the same in Q1 (59%) and essentially unchanged from 2025.

SG&A tells the more important story. It was $101.8 million, nearly identical to $101.1 million a year ago. On a shrinking revenue base, that's a margin expansion in reverse — SG&A rose to 37.6% of revenue from 33.5%. Adjusted EBITDA fell 11% to $98 million, with its margin dropping to 36% from 37%. The operating engine is not accelerating. It's maintaining speed while the car gets smaller.

The cash flow side is where the pressure shows up most clearly. Operating cash flow was $53.1 million in Q2, down 38% from $86.1 million a year ago. Free cash flow was $32.1 million, down 54% from $70.1 million. For the first half combined, operating cash flow was $108.8 million and free cash flow was $74.4 million. That's still positive, but the quarter-over-quarter deterioration is not a rounding error.

The Harvest problem

Harvest contributed revenue for only 27 of the 91 days in Q2 before the June 3 deconsolidation. That's the mechanical reason revenue declined — it's not just that the underlying medical business is weak, it's that the comparison set changed. Harvest is now accounted for as an equity-method investment, meaning its revenue no longer flows through Trulieve's top line.

Trulieve now operates 207 dispensaries with 3.5 million square feet of cultivation and processing capacity. Retail sales accounted for 94% of Q2 revenue. The footprint is large and the focus is medical-only, but Georgia's expanded medical cannabis program — which Trulieve entered in July with first sales at its Marietta dispensary and supply to over 12 pharmacies — is still too early to move the quarterly needle.

Valuation and the stock

Trulieve's stock opened at $8.40 today and ran to $9.00, up 6.6% on the earnings release. The 52-week range is $7.82 to $12.30, and the stock is down 23.6% over the past four months. It trades at $1.73 billion market cap, 1.48x trailing revenue, and 4.6x EV/EBITDA.

That EV/EBITDA multiple would be rich for a company with 10% revenue decline and deteriorating cash flow. It's only tolerable because the tax relief created a path to GAAP-adjacent profitability that didn't exist before. But the multiple also reflects the Schedule III thesis — the market is pricing the tax benefit as permanent and the revenue gap as temporary.

The question is which part of that thesis is more likely to be wrong. Tax relief seems durable. Revenue is the risk. TTM revenue growth is negative 1.4%. SG&A isn't bending. Free cash flow is declining quarter over quarter. And uncertain tax-position liabilities of $598.2 million — mostly deferred Section 280E obligations — still sit on the balance sheet, nearly double the $325.4 million cash balance.

What would change the story

The factor stack is mixed. Profitability on an adjusted basis is a pass, and it's improving thanks to a one-time regulatory change rather than operating acceleration. Revenue growth and cash flow are degrading. The balance sheet is clean enough — $352.9 million in cash, minimal leverage, current ratio of 5.3x — but the uncertain tax liabilities are a real overhang.

The 6.6% pop today was the market rewarding the profit flip. But the profit flip came from tax law, not from the business growing faster. That's a sustainable floor, not a growth thesis.

Georgia is the closest thing to a near-term organic catalyst. If the state's expanded medical program scales quickly, it could offset Harvest's absence and bend SG&A lower as a revenue percentage. Texas is mentioned in management commentary but remains speculative. Federal rescheduling beyond Schedule III would be the home run, but nobody has a timeline for that.

AInvest's aggregate signal labels Trulieve a Buy, but the composite score of 2.77 (out of 5) is lukewarm — it reflects the same mixed picture the factor stack shows.

Portfolio role

Trulieve belongs in a regulatory-option sleeve, not a growth sleeve. The company is a bet that federal cannabis policy continues to normalize, that the medical-focused operator model wins market share as states expand, and that Georgia and potential Texas entries compound the Florida base. If you're positioned on Schedule III being a one-time event rather than a regime shift, this stock makes sense.

The trigger to reduce would be another quarter of negative revenue growth with SG&A still flat or rising as a percentage of sales. The trigger to add would be Georgia revenue material enough to show sequential acceleration in Q3, or free cash flow stabilizing above the $50 million quarterly run rate. Until then, the profit story is real but the growth story isn't written yet.